Cyclophosphamide
โ ๏ธ Warning: Cyclophosphamide is a highly toxic alkylating agent. It must only be prescribed by experienced specialists under close supervision.
๐ก Famous for causing haemorrhagic cystitis โ prevention is essential.
๐ About
Always check the BNF link here before use.
- ๐ Alkylating agent with profound bone marrow suppression.
- โฌ๏ธ Immunity โ high risk of infection, bleeding, and secondary malignancy.
- ๐ซ Potent teratogen โ contraindicated in pregnancy and breastfeeding.
โ๏ธ Mode of Action
- Prodrug activated by hepatic cytochrome P450 to 4-hydroxy-cyclophosphamide.
- Metabolites crosslink DNA โ inhibit DNA replication & cell division.
- โฑ๏ธ Effects may be delayed (up to 6 weeks in rheumatology indications).
๐ฉธ Malignant Indications
- Hodgkinโs disease & non-Hodgkinโs lymphomas (incl. Burkittโs lymphoma).
- Leukaemias (CLL, CML, AML, ALL in children).
- Multiple myeloma, mycosis fungoides, neuroblastoma.
- Breast carcinoma, ovarian adenocarcinoma, retinoblastoma.
๐งฌ Non-Malignant / Autoimmune Indications
- Severe, refractory rheumatoid arthritis.
- Systemic lupus erythematosus (esp. nephritis), myositis, systemic sclerosis, vasculitis.
- Steroid-resistant nephrotic syndrome, progressive IgA nephropathy.
- Life- or organ-threatening autoimmune disease when other therapies fail.
๐ Dose (Specialist Protocols)
โ ๏ธ Always follow local oncology/rheumatology protocols. Below are typical regimens:
- Rheumatology: 1โ1.5 mg/kg/day PO for systemic disease.
- IV pulses: 0.5โ1 g every 2 weeks โ then monthly (depending on response).
- Cancer: protocols vary (see oncology guidelines).
- Course length: often 3โ6 months to induce remission.
๐ Interactions
- โ Avoid live vaccines (e.g. yellow fever, varicella).
- ๐ Additive marrow suppression with other cytotoxics or radiotherapy.
- Possible increased cardiotoxicity with anthracyclines.
โ ๏ธ Contraindications
- ๐ซ Pregnancy or breastfeeding.
- ๐ซ Severe bone marrow suppression.
- ๐ซ Active severe infection.
โ ๏ธ Side Effects
- ๐คข Nausea, vomiting, mucositis.
- ๐ฉธ Myelosuppression โ neutropenia, infections, bleeding; later risk of AML/MDS.
- ๐ซ Pulmonary fibrosis, ๐ cardiac toxicity (high doses).
- ๐ก Haemorrhagic cystitis โ prevent with vigorous hydration + MESNA.
- โฌ๏ธ Long-term risk: bladder carcinoma, skin cancers, lymphomas.
- โ ๏ธ Infertility (permanent risk, esp. in young patients).
- ๐งโ๐ฆฒ Hair loss, menstrual irregularity, mouth ulcers.
- ๐งช Immunosuppression โ seek medical help if sore throat, fever, or exposure to chickenpox/shingles.
๐ References